A contrary view that all apoB-containing lipoproteins have an approximately equal quantitative association with CHD risk3–5 is based on evaluation of a smaller number of genetic instruments (SNPs linked to genes with known effects on lipid metabolism such as the LDL receptor or lipoprotein lipase genes). The gene discussed is LPL; the disease is coronary artery disorder.